AstraZeneca
AstraZeneca battling ‘headwinds’
February 7, 2014Sales and Marketing AstraZeneca, Soriot, farxiga, q4, results, xigduo
AstraZeneca is to shed another 550 jobs as its latest corporate restructure takes shape, bringing to 5,600 the number of …
AstraZeneca ‘simplifies decision-making’
February 4, 2014Sales and Marketing AstraZeneca, BMS, Byetta, Forxiga, Onglyza, diabetes
AstraZeneca has completed its $4.3 billion acquisition of Bristol-Myers Squibb’s diabetes business, giving the company control over several big-name brands …
AZ bullish on its future – but analysts wary
January 15, 2014Sales and Marketing AstraZeneca, Roche, analysts, jp morgan
AstraZeneca is combating fears over its long-term future by assuring investors that it has the pipeline and the tenacity to …
FDA approves Farxiga
January 10, 2014Sales and Marketing AstraZeneca, BMS, FDA, Forxiga, diabetes
The FDA has approved Farxiga, the diabetes treatment developed by AstraZeneca and Bristol-Myers Squibb as part of their soon-to-be-defunct diabetes …
AstraZeneca strikes cancer vaccine pact
January 8, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, MedImmune, oncology
AstraZeneca’s biologics arm MedImmune has struck an oncology research deal with UK biotech company Immunocore. The deal, which could be …
AZ and Horizon in cancer tie-up
January 8, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, horizon, medimunne
AstraZeneca has signed a deal with British biotech firm Horizon Discovery to look at a number of genotypes to see …
BMS sells diabetes stake to partner AstraZeneca
December 19, 2013Sales and Marketing AstraZeneca, BMS, Forxiga, Onglyza, diabetes, komboglyze
AstraZeneca will buy out Bristol-Myers Squibb’s stake in its diabetes alliance in a potential $4.3 billion deal. AZ will pay …
AstraZeneca donates doomed lab to Plymouth University
December 12, 2013Research and Development, Sales and Marketing AstraZeneca, lab, plymouth, university
AstraZeneca has pledged to donate its Devon-based Environmental Laboratory to Plymouth University, after announcing the site’s closure in October. The …
AstraZeneca sells arthritis drug for $35 million
November 20, 2013Sales and Marketing AstraZeneca, RA, arthritis, horizon, vimovo
AstraZeneca has sold rights to its arthritis treatment Vimovo to speciality pharma firm Horizon Pharma for $35 million. AZ retains …
AstraZeneca ups cancer drug production at Alderley Park
November 11, 2013Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, Zoladex, alderley park
AstraZeneca says it plans to invest around £120 million in a new cancer drug manufacturing facility at its plant in …
More changes at the top as AstraZeneca profits slip
November 1, 2013Sales and Marketing AstraZeneca, Crestor, Q3, profits
AstraZeneca’s third quarter revenues and profits fell below analysts’ expectations yesterday, but mitigated the news with the appointment of a …
AstraZeneca hires former GSK head as CFO
November 1, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, GSK, dunoyer
AstraZeneca has confirmed that Marc Dunoyer has been appointed chief financial officer and will join the company’s Board as an …
AstraZeneca to close Brixham environmental lab
October 25, 2013Manufacturing and Production API, AstraZeneca, brixham
AstraZeneca’s UK workers are facing more disruption following the company’s decision to close down a laboratory in Brixham focussing on …
Phoenix from Charnwood’s ashes
October 25, 2013Research and Development, Sales and Marketing AstraZeneca, Charnwood, medilink
The shuttering of AstraZeneca’s R&D site at Charnwood in Leicestershire has had a positive effect on the region’s life sciences …
AZ begins late-stage trial of new cancer drug
October 22, 2013Research and Development, Sales and Marketing AstraZeneca, Cancer, NSCLC, selumetinib
AstraZeneca has begun a Phase III study for its investigational lung cancer pill selumetinib in patients with a genetic sub-type …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
